



HAL
open science

A pH-Sensitive Peptide-Containing Lasso Molecular Switch

Frédéric Coutrot, Caroline Clavel, Karine Fournel-Marotte

► **To cite this version:**

Frédéric Coutrot, Caroline Clavel, Karine Fournel-Marotte. A pH-Sensitive Peptide-Containing Lasso Molecular Switch. *Molecules*, 2013, 18, pp.11553-11575. 10.3390/molecules180911553. hal-00862684

HAL Id: hal-00862684

<https://hal.science/hal-00862684>

Submitted on 27 May 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License

Article

A pH-Sensitive Peptide-Containing Lasso Molecular Switch

Caroline Clavel, Karine Fournel-Marotte and Frédéric Coutrot *

Supramolecular Machines and ARchitectures Team, Institut des Biomolécules Max Mousseron, (IBMM) UMR 5247 CNRS-UM1-UM2, Université Montpellier 2, Place Eugène Bataillon, Case Courrier 1706, F-34095 Montpellier Cedex 5, France

* Author to whom correspondence should be addressed; E-Mail: frederic.coutrot@univ-montp2.fr; Tel.: +33-0-4-6714-3843; Fax: +33-0-4-6763-1046.

Received: 24 July 2013; in revised form: 9 September 2013 / Accepted: 11 September 2013 /

Published: 17 September 2013

Abstract: The synthesis of a peptide-containing lasso molecular switch by a self-entanglement strategy is described. The interlocked [1] rotaxane molecular machine consists of a benzometaphenylene[25]crown-8 (BMP25C8) macrocycle surrounding a molecular axle. This molecular axle contains a tripeptidic sequence and two molecular stations: a *N*-benzyltriazolium and a pH-sensitive anilinium station. The tripeptide is located between the macrocycle and the triazolium station, so that its conformation can be tailored depending on the shuttling of the macrocycle from one station to the other. At acidic pH, the macrocycle resides around the anilinium moiety, whereas it shuttles around the triazolium station after deprotonation. This molecular machinery thus forces the lasso to adopt a tightened or a loosened conformation.

Keywords: [1]rotaxane; lasso; molecular switch; self-entanglement; peptide

1. Introduction


As part of our research concerning the synthesis of interlocked molecular machines, we were interested in the synthesis of lasso compounds. In Nature, lasso molecules, more precisely lasso peptides, can be secreted by bacteria. These compounds contain 16 to 21 amino acid residues which define a stable lasso molecular shape (*i.e.*, a peptide macrocycle covalently linked to a peptide axle which threads the macrocycle) with a very constrained conformation, in comparison with their unthreaded analogues. The macrocycle is threaded by the peptide tail, whose bulky side-chains act as

molecular barriers to trap the macrocycle around the peptide axle in the lasso conformation. The encircled peptide axle then adopts a looped conformation, conferring to the lasso a very compact tridimensional structure, which is responsible for its biological activity. Beyond their remarkable stability against proteolytic degradation, chemical and thermal denaturation [1–3], some lasso peptides proved to inhibit HIV replication [4] or the Gram-negative RNA polymerase [5]. As a particular example of lasso peptide, the ribosomally synthesized [6,7] antimicrobial peptide microcin J25 (MccJ25), which was isolated from *E. coli* in 1992, [8] has been extensively studied during the past years [9–12]. The amino acid sequence was first proposed by Blond *et al.* in 1999, who proposed a 21-residue, head-to-tail cyclic structure [13]. Four years later, three teams (Montelione and Ebright *et al.*, Craik *et al.*, and Darst *et al.*) demonstrated concomitantly that the initial proposed covalent and three-dimensional structure was incorrect, and that the peptide was in fact a lasso compound [14–16]. In view of their structural-dependent properties, lasso peptides could be considered as potential scaffold for therapeutic peptides [17]. With this aim, several biosyntheses and structure-activity analysis of a wide range of lasso peptides were realized [18–20]. Recently, Marahiel *et al.* have highlighted the interest of incorporating a RGD peptide sequence in the turn of the lasso MccJ25 [21]. They substituted the native Gly¹²Ile¹³Gly¹⁴ by the ArgGlyAsp sequence in the loop of the lasso, using site-directed mutagenesis of the precursor protein MccJ. Interestingly, they found that the use of a lasso scaffold triggers a specific conformation of the incorporated bioactive peptide sequence, which is responsible for specific and distinct physical, biological and chemical properties, with respect to their linear shape. To date, no lasso peptide has been synthesized using chemical protocols, probably because of the highly difficult synthetic challenge, especially due to the folding of peptides which disturbs the necessary preorganization between the components to be assembled into an interlocked lasso. However, other more or less related works concerning peptides and interlocked molecular architectures such as peptido[2]rotaxanes have already been reported. Leigh *et al.* have been the first to surround the dipeptide unit GlyGly with a tetramide macrocycle, using hydrogen bond interactions between the peptide amide carbonyl groups of the thread and the NH of the macrocycle [22]. They next extended their efficient five-components hydrogen bond directed clipping strategy to the synthesis and the study of a wide range of dipeptides [23–26]. They also prepared many [2]rotaxane molecular shuttles in which the encircled thread contains different peptide moieties as molecular stations [27–35]. Inversely, some [2]rotaxanes, in which the macrocycles consist of cyclic peptides were reported too [36]. More recently, Moretto *et al.* employed the Leigh's strategy to yield an oligopeptide [2]rotaxane shuttle, in which the longest part of the axle is a rigid helical peptide [37]. It is also noteworthy that some biological applications of the peptide rotaxanes emerged. Indeed, Leigh *et al.* prepared a pentapeptide [2]rotaxane derived from the Met-enkephalin in which the peptide core is protected against peptidase-catalyzed hydrolysis, until it is released by the action of a galactosidase [38,39]. Anderson *et al.* reported an enzymatic synthesis, using α -chymotrypsin, of a peptide rotaxane based on a cyclodextrin and a peptide thread containing a diazo moiety. They also described the resistance of the obtained peptide rotaxane against enzyme-catalyzed hydrolysis depending on the photoisomerization of the diazo moiety [40]. Meanwhile, Smithrud *et al.* designed rotaxanes as peptide carriers, using a grafted crown ether and a calix[4]arene, cyclophane, or cleft as a blocking group [41]. It remains from all these studies that protection of peptides against enzymatic degradation, on one hand, and the

tailoring of the shape of peptides, on another hand, are two main problems to tackle for the conception of new efficient peptide drugs.

Since the properties of a molecule highly rely on its topology, we were interested in combining a lasso molecular architecture that contains a peptide sequence with the molecular machinery. Therefore, we report, in this paper, a first synthetic approach of a lasso molecule containing, in its turn, the simplest GlyGlyGly peptide as a model sequence (Figure 1).

Figure 1. Cartoon representation of the molecular lasso targets and of the synthetic strategy used to prepare pH-sensitive peptide-containing lasso molecular switch.



The lasso has also been designed so that it could be possible to act as a pH-sensitive molecular shuttle. Thus, the shuttling of the macrocycle along the threaded axle could trigger a variation in the conformation of the lasso (more or less tightened), hence causing a more or less bent conformation of the peptide. This concept should then be attractive for switching the properties of a peptide part of a lasso after applying an external *stimulus*.

The molecular machinery described in this paper is based on interactions between a crown ether macrocycle and our already reported system of molecular stations [42]. Indeed, the lasso compound is composed of a benzometaphenylene[25]crown-8 (BMP25C8) [43–46] macrocycle which surrounds a molecular axle containing two molecular stations for the BMP25C8. The anilinium moiety [47–49] is the best molecular station and is used as the molecular template for the rotaxane formation. The *N*-benzyltriazolium station is of poorer affinity, as long as the anilinium remains protonated. At the protonated state, the lasso lies in a loosened conformation without many constraints for the conformation of the peptide. However, after deprotonation, the BMP25C8 shuttles around the triazolium station, causing a tightening of the lasso and forcing the peptide to adopt a more bent conformation.

2. Results and Discussion

2.1. Synthetic Strategy to Synthesize the Lasso Compounds

The necessary driving force to yield our interlocked lasso molecules lies on the interactions between a crown ether and an ammonium moiety [50,51]. Even though the binding affinities of the molecular stations are lower for the larger macrocycle BMP25C8 than for the smaller DB24C8, the formation of the [1]rotaxane was still possible. In the present paper, the strategy used to interlock the molecular structure is based on a self-entanglement [52] of a “hermaphrodite” molecule (*i.e.*, a molecule containing both a macrocycle as host and an axle holding the anilinium template as guest) (Figure 1). The size of the cavity of the macrocycle is crucial for the successful self-entanglement strategy, especially because the end of the molecular axle is already capped with a bulky stopper, which stops the axle from threading through the macrocycle by this extremity. However, the BMP25C8 macrocycle appears large enough to allow for the rotation of the meta-substituted aromatic ring. This internal rotational movement in the BMP25C8 leads to the threading of the covalently linked anilinium-containing molecular axle, until the macrocycle surrounds the anilinium molecular template. At this stage, the lasso compound remains in equilibrium with the initial un-interlocked hermaphrodite molecule. We can then take advantage of the presence of the triazole moiety, which is located between the macrocycle and the anilinium station, in order to create the second molecular station (*i.e.*, triazolium) on one hand, and especially on the other hand, to incorporate a bulky side-chain that acts as a kinetic molecular barrier [53] and traps the interlocked architecture.

2.2. Preliminary Results Obtained on a Non-Peptidic Lasso Molecular Switch

We have recently reported the feasibility of the self-entanglement strategy on a non-peptidic molecule [54] (Scheme 1, left side). The hermaphrodite unthreaded molecule **4u**, consisting of the BMP25C8 macrocycle linked to the anilinium molecular axle, was prepared in a two-step sequence from the already synthesized alkyne **1** [55]. This alkyne compound possesses a carbamoylated di-*tert*-butylaniline moiety, so that no template effect can occur at this time.

The first step was a copper(I)-catalyzed Huisgen [56–59] 1,3-dipolar cycloaddition, also called “CuAAC click chemistry [60,61], between the alkyne **1** and the azido BMP25C8 **2** in dichloromethane in the presence of 2,6-lutidine and Cu(MeCN)₄PF₆. This step led very efficiently to the triazole compound **3**, which was then submitted to a decarbamoylation that revealed the anilinium template moiety. A slow equilibrium, on the NMR time scale, between the interlocked lasso **4** and the uncomplexed molecule **4u** could then be observed. Since the di-*tert*-butylanilinium end of the molecular axle is too bulky to thread into the macrocycle, the only way to assemble the lasso architecture is through self-entanglement. It was demonstrated that the best conditions to obtain the lasso **4** was the use of dichloromethane, as a good hydrogen bond promoting solvent, and at high dilution. In these optimal conditions, a maximum *ratio* **4/4u** of 45/55 was measured. Subsequent trapping of the lasso structure was realized by taking advantage of the localization of the triazole moiety between the macrocycle and the anilinium molecular station. The benzylation of the triazole afforded the lasso **5** in a 27% yield. Here, no more equilibrium between interlocked compound **5** and uncomplexed compound **5u** was possible, due to the incorporation of the benzyl moiety on the triazole

2.3. Extension to the Preparation of a pH-Sensitive Tripeptide-Containing Lasso Molecular Switch

2.3.1. Synthetic Part

We then aimed to incorporate a peptide sequence in the turn of the lasso molecular architecture. The simplest GlyGlyGly tripeptidic sequence was chosen in order to fit with the structural prerequisites for the self-entanglement synthetic strategy. Indeed, no such self-entanglement should be authorized with bulky amino acid side-chains. With the aim to be able to tailor the conformation of the peptide depending on the molecular machinery applied to the lasso, the peptide sequence has been localized the closest to the macrocycle BMP25C8, that is to say in the loop of the lasso. Thus, the azido-containing macrocycle **10** was first synthesized according to a three-step sequence from the commercially available BocGlyGlyGlyOH. Activation of the C-terminal side of the tripeptide using Castro's reagent BOP [62] in the presence of triethylamine and 2-azidoethylamine [63] afforded the azido tripeptide **8** in quantitative yield. The further decarbamylation using trifluoroacetic acid provided the ammonium intermediate **9**, which was then submitted to a coupling reaction with the carboxylic acid substituted BMP25C8 to yield the azido macrocycle **10**. Due to the very poor solubility of compound **10** in dichloromethane and in acetonitrile at room temperature, the copper(I)-catalyzed Huisgen 1,3-dipolar cycloaddition was accomplished with alkyne **1** in acetonitrile and at a temperature of 70 °C. In these experimental conditions, 90% of the unthreaded compound **11** was isolated. Decarbamylation of **11** unmasked the anilinium template and allowed for the self-entanglement of the hermaphrodite molecule **12u**. The equilibrium between the lasso **12** and its unthreaded analogue **12u** was studied in details (see Section 2.3.2.). The subsequent benzylation of the lasso **12** allowed for the trapping of the lasso molecular architecture: it was carried out in dichloromethane at high dilution with respect to **12** and using a very large excess of benzyl bromide. Although the conversion rate for the benzylation of the non-peptidic lasso **4** was quasi quantitative (only 5% of the starting triazole compounds **4/4u** were recovered after chromatographic columns), the formation of the benzyl triazolium appears much more tricky in the case of the peptide-containing lasso. Indeed, after 7 days, 33% of the triazole compounds **12/12u** were still detected by NMR spectroscopy. Moreover, several chromatographic columns on both silica gel and sephadex yielded to a mixture composed of 17% of the unthreaded benzyltriazolium **13u** and 17% of the desired triazolium lasso **13**. The separation between these compounds was found to be very tough and only 4% of **13** could be isolated. We were curious about the possibility to realize the benzylation at a higher temperature in order to accelerate the rate of the reaction. Unfortunately, VT ¹H-NMR experiments in C₂D₂Cl₄ on **12/12u** showed that increasing the temperature results in the dramatic decrease of the proportion of the lasso compound **12** (Table 1, entries 3–7). Despite the poorly efficient reaction of benzylation, the deprotonation of the isolated loosened lasso **13** was carried out efficiently by adding the Hünig's [64] base DIEA. Deprotonation of the anilinium triggered the shuttling of the BMP25C8 towards the triazolium moiety, hence causing the tightening of the lasso and inducing the more constraint conformation of the tripeptide (see Section 2.3.3.).

2.3.2. Studies of the Equilibrium between the Unthreaded Compound **12u** and the Lasso **12**

The equilibrium between the unthreaded compound **12u** and the lasso **12** highly depends on the polarity of the solvent (Figure 2), on the concentration (Figure 3), and on the temperature.

Figure 2. $^1\text{H-NMR}$ spectra (600 MHz, 298 K) at 5.10^{-4} M of a mixture of compounds **12/12u** in: (a) CD_3OD . (b) CD_3CN . (c) CD_2Cl_2 . The lettering and numbering correspond to the proton assignments indicated in scheme 1. The orange color corresponds to the unthreaded molecule **12u**, whereas the green color corresponds to lasso compound **12**. The black assignments correspond to both compounds.




Table 1 summarizes the **12/12u** ratios measured in the different solvents from the best hydrogen bond promoting solvents dichloromethane and tetrachloroethane to the more polar solvent methanol and upon variation of the concentration and temperature. As the equilibrium between **12** and **12u** proved to be slow on the NMR time scale, two sets of $^1\text{H-NMR}$ signals were observed for each unthreaded and lasso compounds. The ratio values reported in Table 1 were obtained by $^1\text{H-NMR}$ spectroscopy at 600 MHz by integrating the signal of hydrogens H_{15} or H_{12} .

Figure 3. $^1\text{H-NMR}$ spectra (600 MHz, 298 K) of a mixture of compound **12/12u** in CD_2Cl_2 at: (a) 5.10^{-2} M. (b) 5.10^{-3} M. (c) 5.10^{-4} M. The lettering and numbering correspond to the proton assignments indicated in scheme 1. The orange color corresponds to the unthreaded molecule **12u**, whereas the green color corresponds to lasso compound **12**.




Table 1. Ratio between lasso compound **12** and unthreaded molecule **12u** depending on concentration, solvent and temperature.

Entries	C (12/12u) [M]	T (K)	CD_3OD	CD_3CN	CD_2Cl_2	$\text{C}_2\text{D}_2\text{Cl}_4$
1	5.10^{-2}	298	-	-	35/65	-
2	5.10^{-3}	298	-	-	44/56	-
3	5.10^{-4}	298	0/100	25/75	47/53	55/45
4	5.10^{-4}	318	-	-	-	38/61
5	5.10^{-4}	328	-	-	-	29/71
6	5.10^{-4}	338	-	-	-	14/86
7	5.10^{-4}	348	-	-	-	8/92

Obviously, it can be seen from the data reported in Table 1 that the nature of the solvent has a big influence on the **12/12u** ratio. At 298 K, the best self-entanglement was noticed in the less polar dichloromethane and tetrachloroethane and at the highest dilution (Table 1, entry 3). At a similar concentration, the proportion of the lasso **12** dramatically declines in the more polar acetonitrile and no presence of the lasso was detected in methanol (Figure 2 and Table 1, entry 3). Eventually, increasing the concentration of the sample in dichloromethane tends to be unfavorable to the interlocked lasso architecture (Figure 3 and Table 1, entries 1–3).

Besides, the equilibrium between **12u** and **12** could be highlighted using drift tube ion mobility mass spectrometry (DT IM-MS). By this analytical method, it was possible to separate compounds **12** and **12u**, because they have different velocities which are due to their distinct sizes related to their unlike conformational structures. A similar analytical study was utilized by Leigh *et al.* to distinguish a trefoil knot from its unknotted-macrocycle analogue [65]. Figure 4 shows the DT IM-MS results of various samples of a mixture of compounds **12/12u** at the same concentration (5×10^{-4} M) upon variation of the ratio of a solvent mixture of dichloromethane/acetonitrile. Interestingly, and whatever the polarity of the solvent mixture used for the injection, the lasso compound **12**, whose conformation is smaller and more compact, have a lower arrival time distribution (63 scans). On the contrary, the unthreaded molecule **12u** consists of a larger ion with less conformational restrictions. As a consequence, it takes more time for this ion to travel through the drift cell (arrival time distribution of 67 scans). Moreover, the same trend in the **12/12u** ratio could be detected upon variation of the solvent polarity by this method as that observed by NMR. Indeed, a **12/12u** ratio of 18/82 in favor of **12u** was measured in the more polar acetonitrile, whereas the ratio was inverted in pure dichloromethane. The consistency of this trend observed from the dichloromethane to the acetonitrile, with respect to the NMR study, suggests that the equilibrium between **12** and **12u** is slow on the ion mobility mass spectrometry time scale. The width at half-height of each pick was also measured in pure acetonitrile and dichloromethane: the peak related to the lasso **12** has a slightly narrowest distribution, which reveals a more persistent size and shape, in accordance with the more restraint lasso structure. On the contrary, the slightly broadest distribution observed for the peak of the unthreaded molecule **12u** exhibits its larger degree of flexibility.

2.3.3. $^1\text{H-NMR}$ Investigation of the Molecular Machinery between Lasso Compounds **13** and **14**

The comparison between the $^1\text{H-NMR}$ spectra of the protonated and deprotonated unthreaded molecules **13u**, **14u** with their respective protonated and deprotonated molecular lassos **13** and **14** allowed to demonstrate the lasso interlocked architecture and the localization of the BMP25C8 around the molecular axle (Figure 5).

In the $^1\text{H-NMR}$ spectrum of the protonated molecular lasso **13**, signals for the hydrogen atoms $\text{H}_{\text{A-B}}$ and $\text{H}_{\text{C-F}}$ of the BMP25C8 appear split because they are facing the two non-symmetrical ends of the molecular axle of the interlocked lasso architecture. Moreover, the localization of the macrocycle around the anilinium station in **13** can be deduced from the direct comparison between the $^1\text{H-NMR}$ spectra of **13** and **13u** [Figure 5(a) and (b)]. Indeed, in the lasso **13**, the signals for the hydrogen atoms H_{21} appear at very high chemical shift ($\delta = 8.60$ ppm). Likewise, hydrogens H_{20} belonging to the anilinium station are shifted downfield with respect to the protonated unthreaded molecule **13u** ($\Delta\delta = 0.15$ ppm), because they interact by hydrogen bonds with the oxygen atoms of the BMP25C8. Concerning the hydrogen H_{I} of the BMP25C8, it is dramatically shifted upfield in **13** ($\Delta\delta = -0.67$ ppm) because it experiences the shielding effect of the anilinium aromatic ring. The same trend is observed for hydrogen atoms $\text{H}_{\text{E-F}}$ of the BMP25C8. Eventually, the hydrogen atoms H_{13} and H_{15-19} are all more or less shielded (respectively $\Delta\delta = -0.17, -0.15, -0.40, -0.50, -0.63$ and -0.30 ppm) because they all undergo the shielding effect of the aromatic rings of the BMP25C8. Among them, it is noteworthy that hydrogen atoms $\text{H}_{16-17-18}$ are the more concerned by this effect.

Figure 4. DT IM-MS of the mixture **12/12u** in: (a) CH₃CN. (b) CH₃CN/CH₂Cl₂ 30/70. (c) CH₃CN/CH₂Cl₂ 20/80. (d) CH₃CN/CH₂Cl₂ 10/90. (e) CH₂Cl₂. Data shows: the average time distribution (in scan units) at a drift voltage of 40V and the peak area (in %) for the detected molecular ion [M–PF₆]⁺.






Figure 5. $^1\text{H-NMR}$ spectra (600 MHz, CD_2Cl_2 , 298 K) of: (a) the protonated unthreaded compound **13u**. (b) the protonated lasso-based compound **13**. (c) the deprotonated lasso-based compound **14**. (d) the deprotonated unthreaded compound **14u**. The coloring, lettering and numbering correspond to the proton assignments indicated in scheme 1.



Deprotonation of the loosened lasso **13** led to the tightened lasso **14**. The direct comparison of the $^1\text{H-NMR}$ spectra between the two lasso [1]rotaxanes **13** and **14** reveals the shuttling of the BMP25C8 [Figure 5(b) and (c)]. Unsurprisingly, $^1\text{H-NMR}$ chemical shifts of hydrogens H_{20} , H_{23} and H_{25} , which belong to the anilinium moiety, are shifted upfield in the deprotonated lasso **14**, due to the deprotonation of the anilinium unit. At the same time, in **14**, H_I is shifted downfield ($\Delta\delta = 0.31$ ppm) because it does not experience anymore the strong shielding effect of the aniline extremity. However, this signal is still at a lower chemical shift than those observed in the unthreaded protonated and deprotonated molecules **13u** and **14u** (respectively $\Delta\delta = -0.36$ and -0.34 ppm) [Figure 5(c) and (d)]. This result can be explained by the new localization of H_I which now experiences the shielding effect of the benzyl triazolium moiety, this latter effect being weaker than those of the anilinium aromatic ring. This observation is corroborated by the upfield shift underwent by the other hydrogen atoms of the aromatic rings of the crown ether H_J , H_A and H_B (respectively $\Delta\delta = -0.18$, -0.04 and -0.16 ppm), which experience the same shielding effect from the triazolium ring. Moreover, the displacement of


the BMP25C8 can account for the upfield shift observed in **14** for the hydrogen atoms of the benzyl molecular barrier H₂₈, H₃₀ (respectively $\Delta\delta = -0.23, -0.24$ ppm) and in a lesser extent H₃₂ (with respect to **13**), due to their localization in the shielding cavity of the aromatic rings of the BMP25C8. Similarly, the hydrogen atoms of the molecular axle located on the other side of the molecular barrier H₁₁ and H₁₂ are both shielded by the BMP25C8: actually, this latter lies on the triazolium moiety and its aromatic rings can reach the other side of the molecular barrier (respectively $\Delta\delta = -0.23, -0.41$ ppm). On the contrary, the hydrogen atoms located between the aniline and the triazolium unit H₁₆, H₁₇, H₁₈ and H₁₉ and in a much lesser extent H₁₃, are shifted downfield in **14** (respectively $\Delta\delta = 0.62, 0.73, 0.82, 0.22$ and 0.13 ppm) because they do not experience anymore the shielding effect of the BMP25C8. The direct comparison between the ¹H-NMR spectra of the tightened deprotonated lasso **14** and the deprotonated unthreaded analogue **14u** corroborates the localization of the BMP25C8 [Figure 5(c) and (d)].

Figure 6. ¹H-NMR ROESY experiment (600 MHz, CD₂Cl₂, 298 K) of the protonated loosened molecular lasso **13**. The coloring, lettering and numbering correspond to the proton assignments indicated in Scheme 1.



The ROESY $^1\text{H-NMR}$ experiments provided complementary and consistent insights into the structure of the lasso molecular switch **13/14** (Figures 6 and 7). The ROESY $^1\text{H-NMR}$ experiment carried out on the protonated lasso (Figure 6) provided the evidences of the lasso architecture with a localization of the BMP25C8 around the anilinium station (relevant correlation peaks highlighted in cyan). It is particularly true for the correlation peaks between respectively H_{23} and H_{27} of the anilinium site with $\text{H}_{\text{C-H}}$ of the BMP25C8, or between H_1 of the BMP25C8 with H_{20} , H_{23} and H_{27} . Interestingly, no correlation peak between the BMP25C8 and the triazolium site was observed, which is consistent with the localization of the macrocycle around the anilinium moiety.

Figure 7. $^1\text{H-NMR}$ ROESY experiment (600 MHz, CD_2Cl_2 , 298 K) of the deprotonated tightened molecular lasso **14**. The coloring, lettering and numbering correspond to the proton assignments indicated in Scheme 1.



After deprotonation (Figure 7), the relevant highlighted cross peaks relative to the loosened lasso disappear, whereas new correlation peaks demonstrate the new main localization of the macrocycle around the triazolium. In particular, new correlation peaks are observed for the hydrogens H_{C-H} belonging to the BMP25C8 with respectively the triazolium hydrogen H_{13} , the benzyl barrier H_{28} and H_{30} , and the next hydrogen H_{15} . At the same time, hydrogen atoms H_{E-F} correlate with H_{31-32} of the aromatic benzyl molecular barrier. The aromatic hydrogen H_I of the BMP25C8 is now correlated with the hydrogen atoms H_{15} , H_{16} and H_{17} , whereas the other aromatic hydrogens H_A and H_B of the BMP25C8 are correlated with the benzyl barrier H_{28} . In a consistent way, the aromatic hydrogen H_J of the BMP25C8 is correlated with H_{12} , whereas the last aromatic hydrogen of the BMP25C8 H_A is now correlated with H_{11} . The whole NMR studies are consistent with the two main localizations of the BMP25C8 around either the anilinium or the triazolium station upon variation in pH.

Concerning the peptide part GlyGlyGly of the lasso molecule, the overlapping in ROESY spectra between methylene hydrogens H_2 , H_5 , H_8 and the very split methylene hydrogens H_{C-H} of the BMP25C8 unfortunately prevents us from giving dependable assumptions concerning an eventual conformational change of the tripeptide sequence. However, slight changes in chemical shifts could be observed when comparing the 1D 1H -NMR spectra of the protonated loosened lasso **13** with the deprotonated tightened lasso **14**. The 1H -NMR chemical shift of methylene hydrogens H_2 remained almost unchanged in **14** ($\Delta\delta = +0.02$ ppm), whereas H_5 and H_8 are more or less shielded in **14** ($\Delta\delta = -0.05$ and -0.18 ppm). This latter observation can be assigned to the shielding effect of the aromatic of the BMP25C8, corroborating the new localization of the BMP25C8.

3. Experimental

3.1. General

All reactions were achieved under an atmosphere of argon unless otherwise indicated. Dichloromethane was distilled over P_2O_5 and was degassed by bubbling Ar for 20 min. Analytical thin-layer chromatography (TLC) was performed on Merck silicagel 60 F254 plates. Compounds were visualized by dipping the plates in an ethanolic solution of ninhydrine, followed by heating. 1H -NMR and ^{13}C -NMR spectra were obtained from a Bruker Avance III spectrometers (respectively at 400.13 MHz or 600.13 MHz and 100.62 MHz or 150.95 MHz). Chemical shifts of 1H -NMR and ^{13}C -NMR are given in ppm by using CHD_2OH or CH_2Cl_2 as references (3.31 ppm and 5.32 ppm respectively for 1H spectrum and 49 ppm and 54 ppm respectively for ^{13}C spectrum). Coupling constants (J) are reported in hertz (Hz). Standard abbreviations indicating multiplicity were used as follows: s (singlet), br (broad), d (doublet), t (triplet), q (quartet), m (multiplet). High-resolution mass spectra (HRMS) and mass spectra were recorded on a Q-TOF Micro (water) apparatus.

3.2. Synthesis and Characterizations of [1]Rotaxanes **13** and **14**

Boc-GlyGlyGly-NH-CH₂CH₂-N₃ (**8**). 2-Azidoethylamine was first prepared by adding sodium azide (800 mg, 12.2 mmol, 2.3 equiv) to a solution of 2-bromoethylamine hydrobromide (1.08 g, 5.3 mmol, 1 equiv) in H_2O (20 mL). The resulting solution was then stirred overnight at 65 °C. After cooling down to RT, NaOH (232 mg, 5.8 mmol, 1.1 equiv) was added to the reaction mixture. The resulting aqueous

solution was saturated with NaCl and extracted with CHCl_3 (3×20 mL). The organic layer was dried over anhydrous MgSO_4 and used directly for the next step without being concentrated. The solution containing the 2-azidoethylamine (5.3 mmol, 1.5 equiv) was diluted with CHCl_3 (total volume: 150 mL) before adding successively Boc-glycylglycylglycine (1 g, 3.5 mmol, 1 equiv) and triethylamine (1.43 mL, 10.6 mmol, 3 equiv). The mixture was then stirred until complete dissolution of the tripeptide (15 min). BOP (1.88 g, 4.6 mmol, 1.3 equiv) was added and the mixture was stirred at RT for 18 h. The resulting white precipitate **8** was filtered, washed with CH_2Cl_2 and dried under vacuum. It was used in the next step without further purification (1.25g, quantitative). R_f : 0.40 ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ 9/1). $^1\text{H-NMR}$ (600 MHz, CD_3OD , 298K): δ ppm = 3.90 & 3.86 & 3.75 (3s, 3x2H, H_2 H_5 H_8), 3.45–3.34 (m, 4H, H_{11} H_{12}), 1.45 (s, 9H, $\text{H}_{\text{CH}_3\text{-Boc}}$). $^{13}\text{C-NMR}$ (150 MHz, CD_3OD , 298K): δ ppm = 173.6 & 172.2 & 171.9 (C_3 C_6 C_9), 158.8 ($\text{C}_{\text{O-Boc}}$), 81.0 ($\text{C}_{(\text{CH}_3)_3\text{-Boc}}$), 51.3 (C_{12}), 44.9 & 43.8 & 43.4 (C_2 C_5 C_8), 39.9 (C_{11}), 28.7 ($\text{C}_{\text{H}_3\text{-Boc}}$). MS (ESI): $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{13}\text{H}_{24}\text{N}_7\text{O}_5$: 358.18, found: 358.19.

TFA, H-GlyGlyGly-NH-CH₂CH₂-N₃ (**9**). TFA (5 mL) was added to a suspension of the Boc-GlyGlyGly-NHCH₂CH₂N₃ **8** (1.25g) in CH_2Cl_2 (20 mL), leading to complete dissolution of this compound. After stirring for 15 min at RT, the reaction mixture was concentrated and co-evaporated 5 times with CH_2Cl_2 (20 mL) in order to remove the excess of TFA. The resulting white solid **9** (1.15 g, quantitative) could be used without further purification. R_f : 0.09 ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ 9/1). $^1\text{H-NMR}$ (600 MHz, CD_3OD , 298K): δ ppm = 3.98 & 3.88 & 3.78 (3s, $3 \times 2\text{H}$, H_2 H_5 H_8), 3.39 (s, 4H, H_{11} H_{12}). $^{13}\text{C-NMR}$ (150 MHz, CD_3OD , 298K): δ ppm = 171.9 & 171.8 & 168.4 (C_3 C_6 C_9), 161.0 (q, $^2J_{\text{C-F}} = 38.3$ Hz, $\text{C}_{\text{O}_2\text{-TFA}}$), 117.1 (q, $^1J_{\text{C-F}} = 287.6$ Hz, $\text{C}_{\text{F}_3\text{-TFA}}$), 51.4 (C_{12}), 43.6 & 43.4 & 41.6 (C_2 C_5 C_8), 39.9 (C_{11}). MS (ESI): $[\text{M-TFA}]^+$ calcd for $\text{C}_8\text{H}_{16}\text{N}_7\text{O}_5$: 258.13, found: 258.13.

Azido macrocycle (**10**). The preliminary synthesized carboxylic acid macrocycle [8] (894 mg, 1.82 mmol, 1 equiv) and compound **9** (707 mg, 2 mmol, 1.1 equiv) were dissolved in DMF (20 mL). Then, triethylamine (755 μL , 5.45 mmol, 3 equiv) and BOP (973 mg, 2.36 mmol, 1.3 equiv) were added and the mixture was stirred at RT for 17h. DMF was evaporated under *vacuum* and the resulting yellow oil was diluted with CH_2Cl_2 (100 mL), before being successively washed with an aqueous solution of HCl 1M (100 mL), a saturated aqueous solution of NaHCO_3 (100 mL) and brine (100 mL). The organic layer was then dried over MgSO_4 and concentrated to yield a beige precipitate, which was then triturated, washed with Et_2O (200 mL) and dried under vacuum. The compound **10** was pure enough to be used without further purification (1.33g, quantitative). R_f : 0.63($\text{CH}_2\text{Cl}_2/\text{MeOH}$ 9/1). $^1\text{H-NMR}$ (600 MHz, CD_3OD , 298K): δ ppm = 7.04 (d, 2H, $^4J_{\text{HJ-HI}} = 2.1$ Hz, H_J), 6.98–6.92 (m, 2H, H_A), 6.91–6.85 (m, 3H, H_I H_B), 4.22–4.16 (m, 4H, H_H), 4.14–4.08 (m, 4H, H_C), 4.04 (s, 2H, H_2), 3.91 & 3.89 (2s, $2 \times 2\text{H}$, H_5 H_8), 3.84–3.77 (m, 8H, H_D H_G), 3.69 (s, 8H, H_E H_F), 3.35–3.32 (2m, $2 \times 2\text{H}$, H_{11} H_{12}). $^{13}\text{C-NMR}$ (150 MHz, CD_3OD , 298K): δ ppm = 172.9 & 172.2 & 171.9 & 170.4 (C_K C_3 C_6 C_9), 161.6 & 150.5 & 136.6 ($\text{C}_{\text{IV arom BMP25C8}}$), 123.0 (C_B), 116.8 (C_A), 108.0 (C_J), 107.5 (C_I), 72.0 & 71.9 (C_E C_F), 71.0 (2s, C_D C_G), 70.3 (C_C), 69.4 (C_H), 51.3 (C_{12}), 44.5 (C_2), 44.0 & 43.4 (C_5 C_8), 39.9 (C_{11}). MS (ESI): $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{33}\text{H}_{46}\text{N}_7\text{O}_{12}$: 732.32, found: 732.32.

Compound (**11**). To a solution of the azido macrocycle **10** (165 mg, 0.225 mmol, 1 equiv) and the preliminary synthesized alkyne **1** [9] (103 mg, 0.25 mmol, 1.1 equiv) in dry CH_3CN (8 mL) at 70 °C,

were added successively $\text{Cu}(\text{CH}_3\text{CN})_4\text{PF}_6$ (84 mg, 0.225 mmol, 1 equiv) and 2,6-lutidine (3 μL , 0.03 mmol, 0.1 equiv). The mixture was stirred for 24 h at 70 °C. After filtration, the solvent was evaporated under vacuum. The crude was then purified by chromatography on a silicagel column (solvent gradient elution CH_2Cl_2 to $\text{CH}_2\text{Cl}_2/\text{MeOH}$ 80/20) to give compound **11** (234 mg, 90%) as a beige powder. R_f 0.65 ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ 9/1). $^1\text{H-NMR}$ (600 MHz, CD_2Cl_2 , 298K): δ (ppm) = 7.99 (br t, 1H, H₁), 7.70 & 7.46 (2 br t, 2 \times 1H, H₄ H₇), 7.36 (s, 1H, H₁₃), 7.26 (s, 1H, H₂₅), 7.11 (br t, 1H, H₁₀), 7.01–6.95 (m, 4H, H₂₃ H_j), 6.92–6.86 (m, 4H, H_A H_B), 6.83 (s, 1H, H_i), 4.32 (t, 2H, $^3J_{\text{H}12-\text{H}11} = 5.3$ Hz, H₁₂), 4.18–4.13 (m, 4H, H_H), 4.12–4.07 (m, 4H, H_C), 4.00 (d, 2H, $^3J_{\text{H}2-\text{H}1} = 5.1$ Hz, H₂), 3.86–3.74 (m, 12H, H₅ H₈ H_D H_G), 3.67 (s, 8H, H_E H_F), 3.59–3.51 (m, 4H, H₁₁ H₂₀), 2.61 (t, 2H, $^3J_{\text{H}15-\text{H}16} = 7.4$ Hz, H₁₅), 1.64–1.56 (m, 2H, H₁₆), 1.56–1.48 (m, 2H, H₁₉), 1.39 (s, 9H, H_{CH3-Boc}), 1.31 (s, 18H, H₂₇), 1.36–1.25 (m, 4H, H₁₇ H₁₈). $^{13}\text{C-NMR}$ (150 MHz, CD_2Cl_2 , 298K): δ (ppm) = 171.8 & 170.6 & 170.4 & 168.7 (C_K C₃ C₆ C₉), 160.7 & 149.4 & 135.8 (C_{IV arom BMP25C8}), 155.6 (C_{O-Boc}), 151.7 (C₂₄), 142.7 (C₂₂), 122.3 (C₁₃), 122.2 (C_B), 121.9 (C₂₃), 120.3 (C₂₅), 115.4 (C_A), 107.5 (C_J), 106.5 (C_I), 80.0 (C_{(CH3)3-Boc}), 71.3 (2s, C_E C_F), 70.3 & 70.2 (C_D C_G), 69.3 (C_C), 68.9 (C_H), 50.7 (C₂₀), 49.7 (C₁₂), 44.7 (C₂), 43.9 & 43.5 (C₅ C₈), 39.8 (C₁₁), 35.3 (C₂₆), 31.7 (C₂₇), 29.9 (C₁₆), 28.9 (C₁₉), 28.7 (C_{H3-Boc}), 29.5 & 27.1 (C₁₇ C₁₈), 26.0 (C₁₅). MS (ESI): $[\text{M} + \text{H}]^+$ calcd for C₆₀H₈₉N₈O₁₄: 1145.65, found: 1145.65.

Compounds (12/12u). TFA (2.5 mL) was added to a solution of compound **11** (156 mg, 0.14 mmol, 1 equiv.) in CH_2Cl_2 (10 mL). After stirring for 30 min at RT, the reaction mixture was concentrated and co-evaporated 5 times with CH_2Cl_2 (20 mL) in order to remove the excess of TFA. The residue was then diluted in CH_2Cl_2 (10 mL). To this solution was added NH_4PF_6 (114 mg, 0.7 mmol, 5 equiv) and H_2O milliQ (5 mL): the biphasic solution was stirred vigorously for 30 minutes. The aqueous layer was then extracted with CH_2Cl_2 (3 \times 5 mL) and the combined organic layers were dried over MgSO_4 and concentrated to give compounds **12/12u** (162 mg, quantitative) as a beige powder. R_f 0.52 ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ 9/1). HRMS (ESI): $[\text{M} + \text{H} - \text{PF}_6]^{2+}$ calcd for C₅₅H₈₂N₈O₁₂: 523.3026, found: 523.3007.

Unthreaded Compound (12u). $^1\text{H-NMR}$ (600 MHz, 5.10⁻² M in CD_2Cl_2 , 298K): δ (ppm) = 7.98 (br t, 1H, H₁), 7.81 (br t, 1H, H₄ or H₇), 7.69–7.62 (m, 1H, H₄ or H₇), 7.60 (s, 1H, H₁₃), 7.50 (t, 1H, $^4J_{\text{H}25-\text{H}23} = 0.9$ Hz, H₂₅), 7.31–7.26 (m, 1H, H₁₀), 7.29 (d, 2H, $^4J_{\text{H}23-\text{H}25} = 0.9$ Hz, H₂₃), 6.97 (d, 2H, $^4J_{\text{H}J-\text{H}I} = 1.7$ Hz, H_j), 6.83 (s, 4H, H_A H_B), 6.84 (br t, 1H, H_i), 4.40 (br t, 2H, H₁₂), 4.14–4.10 (m, 4H, H_H), 4.10–4.07 (m, 4H, H_C), 4.05–4.02 (m, 2H, H₂), 3.85–3.74 (m, 12H, H₅ H₈ H_D H_G), 3.65 (s, 8H, H_E H_F), 3.62–3.56 (m, 2H, H₁₁), 3.36 (t, 2H, $^3J_{\text{H}20-\text{H}19} = 7.3$ Hz, H₂₀), 2.62 (t, 2H, $^3J_{\text{H}15-\text{H}16} = 6.9$ Hz, H₁₅), 1.76–1.69 (m, 2H, H₁₉), 1.63–1.54 (m, 2H, H₁₆), 1.41–1.32 (m, 2H, H₁₈), 1.35–1.22 (m, 2H, H₁₇), 1.29 (s, 18H, H₂₇). $^{13}\text{C-NMR}$ (150 MHz, 5.10⁻² M in CD_2Cl_2 , 298K): δ (ppm) = 172.0 & 170.8 & 169.2 (4s, C_K C₃ C₆ C₉), 160.8 & 149.1 & 135.5 (C_{IV arom BMP25C8}), 154.3 (C₂₄), 147.5 (C₂₂), 124.3 (C₂₅), 124.0 (C₁₃), 122.3 (C_A), 117.3 (C₂₃), 115.3 (C_B), 107.5 (C_J), 107.1 (C_I), 71.1 (C_E C_F), 70.4 & 70.0 (C_D C_G), 69.2 (C_C), 68.9 (C_H), 53.9 (C₂₀), 50.3 (C₁₂), 44.6 (C₂), 43.9 & 43.4 (C₅ C₈), 39.9 (C₁₁), 35.6 (C₂₆), 31.5 (C₂₇), 28.7 & 28.0 (C₁₆ C₁₇), 25.9 (C₁₈), 25.8 (C₁₉), 24.9 (C₁₅).

Pseudo[1]rotaxane (12). $^1\text{H-NMR}$ (600 MHz, 5.10⁻² M in CD_2Cl_2 , 298K): δ (ppm) = 8.63 (br s, 2H, H₂₁), 8.19 (br t, 1H, H₁), 7.69–7.62 (m, 2H, H₄ H₇), 7.56 (s, 1H, H₁₃), 7.52 (br t, 1H, H₂₅), 7.39 (d, 2H, $^4J_{\text{H}23-\text{H}25} = 1.2$ Hz, H₂₃), 7.19 (t, 1H, $^3J_{\text{H}10-\text{H}11} = 5.8$ Hz, H₁₀), 7.03 (d, 2H, $^4J_{\text{H}J-\text{H}I} = 1.7$ Hz, H_j), 6.96–6.92

(m, 2H, H_A), 6.90–6.86 (m, 2H, H_B), 6.20 (br t, 1H, H_I), 4.43 (br t, 2H, H₁₂), 4.24–3.99 (m, 8H, H_H H_C), 3.94–3.91 (m, 2H, H₂), 3.96–3.67 (m, 12H, H₅ H₈ H_D H_G), 3.73–3.46 (m, 8H, H_E H_F), 3.67–3.56 (m, 2H, H₁₁), 3.56–3.48 (m, 2H, H₂₀), 2.41 (t, 2H, ³J_{H15-H16} = 8 Hz, H₁₅), 1.62–1.52 (m, 2H, H₁₉), 1.38–1.29 (m, 2H, H₁₆), 1.27 (s, 18H, H₂₇), 1.01–0.93 (m, 2H, H₁₇), 0.87–0.80 (m, 2H, H₁₈). ¹³C-NMR (150 MHz, 5.10⁻² M in CD₂Cl₂, 298K): δ (ppm) = 172.4 & 171.2 & 169.1 (4s, C_K C₃ C₆ C₉), 160.1 & 149.1 & 135.7 (C_{IV} arom BMP25C8), 154.2 (C₂₄), 147.8 (C₂₂), 124.9 (C₂₅), 123.9 (C₁₃), 122.8 (C_A), 117.3 (C₂₃), 113.2 (C_B), 108.2 (C₁), 106.8 (C_J), 71.9 & 71.3 (C_E C_F), 70.7 & 70.6 (C_D C_G), 69.1 & 68.6 (C_C C_H), 52.3 (C₂₀), 50.2 (C₁₂), 45.3 (C₂), 44.2 & 44.0 (C₅ C₈), 39.9 (C₁₁), 35.7 (C₂₆), 31.6 (C₂₇), 30.2 (C₁₆), 29.4 (C₁₇), 29.3 (C₁₉), 26.2 (C₁₈), 25.4 (C₁₅).

[1]rotaxane (**13**) A solution of compound **12** (162 mg, 0.14 mmol, 1 equiv) dissolved in CH₂Cl₂ (10 mL) was added dropwise over 24 h to a solution of benzyl bromide (55 mL) and CH₂Cl₂ (218 mL). The mixture was stirred for further 6d at RT. CH₂Cl₂ was then evaporated and the excess of benzyl bromide was removed by filtration on a silicagel column (solvent gradient elution CH₂Cl₂ to CH₂Cl₂/MeOH 80/20). The remaining solid (224 mg) was then diluted in CH₂Cl₂ (16 mL). To this solution was added NH₄PF₆ (133 mg, 0.82 mmol, 5 equiv) and H₂O milliQ (8 mL): the biphasic solution was stirred vigorously for 30 minutes. The aqueous layer was extracted with CH₂Cl₂ (3 × 20 mL) and the combined organic layers were dried over MgSO₄ and concentrated under vacuum. The crude was purified twice by chromatography on a silicagel column (CH₂Cl₂ to CH₂Cl₂/MeOH 80/20) to give several mixed fractions and the isolated [1]rotaxane **13** (7 mg, 4%) as a colourless oil. R_f 0.86 (CH₂Cl₂/MeOH 9/1). ¹H-NMR (600 MHz, CD₂Cl₂, 298K): δ (ppm) = 8.60 (br s, 2H, H₂₁), 8.16 (s, 1H, H₁₃), 7.56 (br t, 1H, H₁), 7.52 (s, 1H, H₂₅), 7.41 (s, 2H, H₂₃), 7.41–7.33 (m, 3H, H₃₂ H₃₁), 7.27 (d, 2H, ³J_{H30-H31} = 7 Hz, H₃₀), 7.27–7.19 (m, 2H, H₄ H₇), 7.03 (br t, 1H, H₁₀), 7.01 (s, 2H, H_J), 6.94–6.88 (m, 2H, H_A), 6.88–6.83 (m, 2H, H_B), 6.20 (s, 1H, H_I), 5.64 (s, 2H, H₂₈), 4.70–4.63 (m, 2H, H₁₂), 4.24–4.18 & 4.18–4.12 & 4.09–4.03 (m, 8H, H_H H_C), 4.01–3.95 (m, 2H, H₂), 3.92–3.73 (m, 12H, H₅ H₈ H_D H_G), 3.78–3.71 (m, 2H, H₁₁), 3.73–3.41 (m, 8H, H_E H_F), 3.51–3.41 (m, 2H, H₂₀), 2.51(t, 2H, ³J_{H15-H16} = 7.5 Hz, H₁₅), 1.48–1.41 (m, 2H, H₁₉), 1.31–1.21 (m, 2H, H₁₆), 1.29 (s, 18H, H₂₇), 0.88–0.80 (m, 2H, H₁₇), 0.75–0.67 (m, 2H, H₁₈). HSQC ¹³C-NMR (150 MHz, CD₂Cl₂, 298K): δ (ppm) = 129.9 (C₃₁ C₃₂), 129.6 (C₁₃), 128.5 (C₃₀), 124.7 (C₂₅), 122.5 (C_A), 117.3 (C₂₃), 113.1 (C_B), 108.8 (C₁), 106.4 (C_J), 72.0 & 71.2 (C_E C_F), 70.6 & 69.7 (C_D C_G), 68.8 & 68.5 (C_H C_C), 55.2 (C₂₈), 53.8 (C₁₂), 52.3 (C₂₀), 44.9 (C₂), 43.5 (C₅ C₈), 39.3 (C₁₁), 31.8 (C₂₇), 28.8 (C₁₇), 27.6 (C₁₉), 27.1 (C₁₆), 25.8 (C₁₈), 23.8 (C₁₅). HRMS (ESI): [M-PF₆]⁺ calcd for C₆₂H₈₈F₆N₈O₁₂P: 1281.6164, found: 1281.6177.

[1]Rotaxane (**14**). To a solution of the [1]rotaxane **13** (3 mg, 2.1 μmol, 1 equiv) in CD₂Cl₂ (0.6 mL) was added 74 μL of a 1% solution of DIEA in CD₂Cl₂ (4.2 μmol, 2 equiv.). R_f 0.73(CH₂Cl₂/MeOH 9/1). ¹H-NMR (600 MHz, CD₂Cl₂, 298K): δ (ppm) = 8.29 (s, 1H, H₁₃), 7.33–7.28 (m, 1H, H₃₂), 7.28–7.24 (m, 2H, H₃₁), 7.20 (br t, 1H, H₁), 7.12 & 7.08 (2 br t, 2H, H₄ H₇), 7.03 (d, 2H, ³J_{H30-H31} = 7.4 Hz, H₃₀), 6.93 (br t, 1H, H₁₀), 6.88–6.84 (m, 2H, H_A), 6.83 (s, 2H, H_J), 6.76 (s, 1H, H₂₅), 6.73–6.68 (m, 2H, H_B), 6.51 (s, 1H, H_I), 6.48 (m, 2H, H₂₃), 5.41 (s, 2H, H₂₈), 4.26 (t, 2H, ³J_{H12-H11} = 6.3 Hz, H₁₂), 4.19–4.14 & 4.10–4.04 (m, 4H, H_H), 4.03–3.97 & 3.94–3.89 (m, 4H, H_C), 4.00 (d, 2H, ³J_{H2-H1} = 5.3 Hz, H₂), 3.86–3.66 (m, 12H, H₅ H₈ H_D H_G), 3.71–3.55 (m, 8H, H_E H_F), 3.55–3.50 (m, 2H, H₁₁), 3.15 (t, 2H, ³J_{H20-H19} = 6.5 Hz, H₂₀), 3.07–3.01 (m, 2H, H₁₅), 1.95–1.82 (m, 2H, H₁₆), 1.69–1.62 (m, 2H, H₁₉),

1.60–1.54 (m, 2H, H₁₇), 1.56–1.49 (m, 2H, H₁₈), 1.28 (s, 18H, H₂₇). HSQC ¹³C-NMR (150 MHz, CD₂Cl₂, 298K): δ (ppm) = 129.4 (C₃₁ C₃₂), 129.3 (C₁₃), 129.1 (C₃₀), 121.9 (C_A), 113.8 (C_B), 112.1 (C₂₅), 108.3 (C₁), 107.8 (C₂₃), 105.1 (C_J), 71.8 & 71.5 & 69.9 (C_E C_F), 70.9 & 70.8 & 68.4 (C_D C_G), 69.8 & 69.7 (C_C), 68.6 & 68.5 (C_H), 54.3 (C₂₈), 52.3 (C₁₂), 44.7 (C₂₀), 44.4 (C₂), 44.6 & 43.4 (C₅ C₈), 38.5 (C₁₁), 31.1 (C₂₇), 30.5 (C₁₉), 29.9 (C₁₇), 27.8 (C₁₈), 26.6 (C₁₆), 23.3 (C₁₅). HRMS (ESI): [M+H]⁺ calcd for C₆₂H₈₈F₆N₈O₁₂P: 1281.6164, found: 1281.6144.

3.3. Synthesis and Characterizations of the Uncomplexed Threads **13u** and **14u**

Protonated Unthreaded Compound (13u): Compound **11** (110 mg, 0.096 mmol, 1 equiv) was dissolved in benzyl bromide (3.4 mL, 300 equiv) and the mixture was stirred for 6d at RT before being directly filtered on a silicagel column to remove the excess of benzyl bromide (solvent gradient elution CH₂Cl₂ to CH₂Cl₂/MeOH 85/15). To a solution of the residue in CH₂Cl₂ (4 mL) was then added TFA (1 mL). The mixture was stirred for 30 minutes before being concentrated and co-evaporated 5 times with 20 mL of CH₂Cl₂ in order to remove the excess of TFA. The residue was then diluted in CH₂Cl₂ (20 mL). To this solution was added NH₄PF₆ (78 mg, 0.48 mmol, 5 equiv) and MilliQ H₂O (10 mL): the biphasic solution was stirred vigorously for 30 minutes. The aqueous layer was extracted with CH₂Cl₂ (3 × 5 mL) and the combined organic layers were dried over MgSO₄ and concentrated to give compound **13u** (106 mg, 80%) as a white foam. R_f 0.86 (CH₂Cl₂/MeOH 9/1). ¹H-NMR (600 MHz, CD₂Cl₂, 298K): δ (ppm) = 8.33 (s, 1H, H₁₃), 7.67 (br t, 1H, H₁), 7.48 (br t, 1H, H₂₅), 7.43 & 7.28 (2 br t, 2H, H₄ H₇), 7.42–7.39 (m, 3H, H₃₁ H₃₂), 7.30–7.26 (m, 2H, H₃₀), 7.25 (d, 2H, ⁴J_{H23-H25} = 1.4 Hz, H₂₃), 7.04 (br t, 1H, H₁₀), 6.99 (d, 2H, ⁴J_{HJ-HI} = 2.1 Hz, H_J), 6.90–6.86 (m, 5H, H_A H_B H_I), 5.64 (s, 2H, H₂₈), 4.67 (t, 2H, ³J_{H12-H11} = 5 Hz, H₁₂), 4.19–4.14 (m, 4H, H_H), 4.11–4.06 (m, 4H, H_C), 4.04 (d, 2H, ³J_{H2-H1} = 5.7 Hz, H₂), 3.88 (d, 2H, ³J = 5.7 Hz, H₅ or H₈), 3.83 (d, 2H, ³J = 5.6 Hz, H₅ or H₈), 3.81–3.75 (m, 8H, H_D H_G), 3.76–3.73 (m, 2H, H₁₁), 3.67 (s, 8H, H_E H_F), 3.31 (t, 2H, ³J_{H20-H19} = 7.8 Hz 2H, H₂₀), 2.66 (t, 2H, ³J_{H15-H16} = 7.4 Hz, H₁₅), 1.78–1.70 (m, 2H, H₁₉), 1.69–1.62 (m, 2H, H₁₆), 1.38–1.30 (m, 4H, H₁₇ H₁₈), 1.28 (s, 18H, H₂₇). ¹³C-NMR (150 MHz, CD₂Cl₂, 298K): δ (ppm) = 171.9 & 171.2 & 171.0 & 169.4 (C_K C₃ C₆ C₉), 160.8 & 149.2 & 135.7 & 135.5 (C_{IV arom BMP25C8}), 154.3 (C₂₄), 145.1 (C₂₂), 131.8 (C₂₉), 130.0 (C₁₃ C₃₁ C₃₂), 128.8 (C₃₀), 124.3 (C₂₅), 122.4 (C_B), 117.2 (C₂₃), 115.4 (C_A), 107.4 (C_J), 107.3 (C₁), 71.1 (C_E C_F), 70.3 & 70.0 (C_D C_G), 69.2 (C_C), 68.9 (C_H), 55.4 (C₂₈), 54.0 (C₂₀), 53.9 (C₁₂), 44.5 (C₂), 43.8 & 43.4 (C₅ C₈), 39.4 (C₁₁), 35.6 (C₂₆), 31.4 (C₂₇), 26.3 (C₁₆), 28.1 & 25.9 (C₁₇ C₁₈ C₁₉), 23.6 (C₁₅). HRMS (ESI): [M–PF₆]⁺ calcd for C₆₂H₈₈F₆N₈O₁₂P: 1281.6164, found: 1281.6173.

Deprotonated Unthreaded Compound (14u): A solution of the thread **13u** (48 mg, 0.034 mmol, 1 equiv) in CH₂Cl₂ (10 mL) was washed with an aqueous solution of 1 M NaOH (5 mL). After separation and further extraction of the remaining aqueous layer with CH₂Cl₂ (10 mL), the combined organic layer were dried over MgSO₄ and then evaporated to obtain the deprotonated unthreaded compound **14u** (43 mg, 99%) as a colourless oil. R_f 0.73 (CH₂Cl₂/MeOH 9/1). ¹H-NMR (600 MHz, CD₂Cl₂, 298K): δ (ppm) = 8.25 (s, 1H, H₁₃), 7.47 (t, 1H, ³J_{H1-H2} = 6 Hz, H₁), 7.44–7.40 (m, 3H, H₃₁ H₃₂), 7.42 (br t, 1H, H₄ or H₇), 7.22 (t, 1H, ³J = 5.4 Hz, H₄ or H₇), 7.30–7.26 (m, 2H, H₃₀), 7.11 (t, 1H, ³J_{H10-H11} = 5.9 Hz, H₁₀), 6.98 (d, 2H, ⁴J_{HJ-HI} = 2 Hz, H_J), 6.91–6.87 (m, 4H, H_A H_B), 6.85 (br t, 1H, H_I), 6.75 (br t, 1H, H₂₅), 6.43 (d, 2H, ⁴J_{H23-H25} = 1 Hz, H₂₃), 5.64 (s, 2H, H₂₈), 4.63 (t, 2H, ³J_{H12-H11} = 5 Hz,

H₁₂), 4.20–4.16 (m, 4H, H_H), 4.11–4.07 (m, 4H, H_C), 4.00 (d, 2H, ³J_{H2-H1} = 5.5 Hz, H₂), 3.83–3.74 (m, 12H, H₅ H₈ H_D H_G), 3.71–3.65 (m, 2H, H₁₁), 3.69 (s, 8H, H_E H_F), 3.06 (t, 2H, ³J_{H20-H19} = 7 Hz, H₂₀), 2.71 (t, 2H, ³J_{H15-H16} = 7.8 Hz, H₁₅), 1.64–1.54 (m, 2H, H₁₆), 1.58–1.49 (m, 2H, H₁₉), 1.40–1.28 (m, 4H, H₁₇ H₁₈), 1.29 (s, 18H, H₂₇). ¹³C-NMR (150 MHz, CD₂Cl₂, 298K): δ (ppm) = 172.1 & 171.0 & 170.8 & 168.9 (C_K C₃ C₆ C₉), 160.8 & 149.4 & 135.7 (C_{IV} arom BMP25C8), 152.2 (C₂₄), 148.8 (C₁₄), 145.2 (C₂₂), 131.8 (C₂₉), 130.2 & 130.1 & 130.0 (C₁₃ C₃₁ C₃₂), 128.6 (C₃₀), 122.2 (C_B), 115.4 (C_A), 112.2 (C₂₅), 107.9 (C₂₃), 107.3 (C_J), 107.0 (C_I), 71.3 (2s, C_E C_F), 70.3 & 70.2 (C_D C_G), 69.3 (C_C), 68.9 (C_H), 55.5 (C₂₈), 54.1 (C₁₂), 44.8 (C₂), 44.5 (C₂₀), 44.4 & 43.6 (C₅ C₈), 39.2 (C₁₁), 35.2 (C₂₆), 31.8 (C₂₇), 29.9 (C₁₉), 27.4 (C₁₆), 29.2 & 27.1 (C₁₇ C₁₈), 23.9 (C₁₅). HRMS (ESI): [M + H]⁺ calcd for C₆₂H₈₈F₆N₈O₁₂P: 1281.6164, found: 1281.6168.

4. Conclusions

We have reported the synthesis of a new lasso molecular switch containing a peptide part, using a two-step sequence strategy: (1) the self-entanglement of a hermaphrodite molecule, (2) the trapping of the interlocked pseudo lasso structure with a molecular barrier. 1D and 2D ¹H-NMR spectroscopies, as well as DT IM-MS studies provided information about the self-interlocking of the molecular lasso and about the pH-dependent molecular machinery. In the protonated state, the lasso remains loosened because the BMP25C8 resides around the best anilinium molecular site. However, deprotonation of the anilinium triggers the shuttling of the BMP25C8 towards the triazolium station, resulting in a more tightened conformation. It appears consistent to say that the peptide part of the lasso, which is located between the macrocycle and the triazolium unit (that is to say in the loop of the lasso), does not play any role in the molecular machinery: however, it undergoes a conformational change from a more extended and flexible shape at acidic pH to a more constraint bent conformation at basic pH. To the best of our knowledge, this is the first example of a pH-sensitive lasso molecular switch incorporating a peptide backbone. Further investigations towards the structure-activity relationship of such a peptide-containing molecular machine are in progress.

Supplementary Materials

Supplementary materials can be accessed at: <http://www.mdpi.com/1420-3049/18/9/11553/s1>.

Conflicts of Interest

The authors declare no conflict of interest.

References

1. Knappe, T.A.; Linne, U.; Zirah, S.; Rebuffat, S.; Xie, X.; Marahiel, M.A. Isolation and structural characterization of capistrain, a lasso peptide predicted from the genome sequence of *Bukholderia thailandensis* E264. *J. Am. Chem. Soc.* **2008**, *130*, 11446–11454.
2. Rosengren, K.J.; Blond, A.; Afonso, C.; Tabet, J.C.; Rebuffat, S.; Craik, D.J. Structure of thermolysin cleaved microcin J25: Extreme stability of a two-chain antimicrobial peptide devoid of covalent links. *Biochemistry* **2004**, *43*, 4696–4702.

3. Rebuffat, S.; Blond, A.; Destoumieux-Garzon, D.; Goulard, C.; Peduzzi, J. Microcin J25, from the macrocyclic to the lasso structure: Implications for biosynthetic, evolutionary and biotechnological perspectives. *Curr. Prot. Pept. Sci.* **2004**, *5*, 383–391.
4. Helynck, G.; Dubertret, C.; Mayaux, J.F.; Leboul, J. Isolation of RP71955, A new anti-HIV-1-peptide secondary metabolite. *J. Antibiot.* **1993**, *46*, 1756–1757.
5. Adelman, K.; Yuzenkova, J.; La Porta, A.; Zenkin, N.; Lee, J.; Lis, J.T.; Borukhov, S.; Wang, M.D.; Severinov, K. Molecular mechanism of transcription inhibition by peptide antibiotic Microcin J25. *Mol. Cells* **2004**, *14*, 753–762.
6. Duquesne, S.; Destoumieux-Garzon, D.; Zirah, S.; Goulard, C.; Peduzzi, J.; Rebuffat, S. Two enzymes catalyze the maturation of a lasso peptide in *Escherichia coli*. *Chem. Biol.* **2007**, *14*, 793–803.
7. Clarke, D.J.; Campopiano, D.J. Maturation of McjA precursor peptide into active microcin MccJ25. *Org. Biomol. Chem.* **2007**, *5*, 2564–2566.
8. Salomon, R.; Farias, R. Microcin 25, A novel antimicrobial peptide produced by *Escherichia coli*. *J. Bacteriol.* **1992**, *174*, 7428–7435.
9. Destoumieux-Garzon, D.; Duquesne, S.; Peduzzi, J.; Goulard, C.; Desmadril, M.; Letellier, L.; Rebuffat, S.; Boulanger, P. The iron-siderophore FhuA is the receptor for the antimicrobial peptide microcin J25: role of the microcin Val¹¹-Pro¹⁶ β -harpain region in the recognition mechanism. *Biochem. J.* **2005**, *389*, 869–876.
10. Bierbaum, G.; Jansen, A. Tying the knot: making of lasso peptides. *Chem. Biol.* **2007**, *14*, 734–735.
11. Cheung, W.L.; Pan, S.J.; Link, A.J. Much of the microcin J25 leader peptide is dispensable. *J. Am. Chem. Soc.* **2010**, *132*, 2514–2515.
12. Ferguson, A.L.; Zhang, S.; Dikiy, I.; Panagiotopoulos, A.Z.; Debenedetti, P.G.; Link, A.J. An experimental and computational investigation of spontaneous lasso formation in microcin J25. *Biophys. J.* **2010**, *99*, 3056–3065.
13. Blond, A.; Peduzzi, J.; Goulard, C.; Chiuchiolo, M.J.; Barthelemy, M.; Prigent, Y.; Salomon, R.A.; Farias, R.N.; Moreno, F.; Rebuffat, S. The cyclic structure of microcin J25, a 21-residue peptide antibiotic from *Escherichia coli*. *Eur. J. Biochem.* **1999**, *259*, 747–755.
14. Bayro, M.J.; Mukhopadhyay, J.; Swapna, G.V.T.; Huang, J.Y.; Ma, L.-C.; Sineva, E.; Dawson, P.E.; Montelione, G.T.; Ebright, R.H. Structure of antibacterial peptide Microcin J25: A 21-residue lariat protoknot. *J. Am. Chem. Soc.* **2003**, *125*, 12382–12383.
15. Rosengren, K.J.; Clark, R.J.; Daly, N.L.; Göransson, U.; Jones, A.; Craik, D.J. Microcin J25 has a threaded sidechain-to-backbone ring structure and not a head-to-tail cyclized backbone. *J. Am. Chem. Soc.* **2003**, *125*, 12464–12474.
16. Wilson, K.-A.; Kalkum, M.; Ottesen, J.; Yuzenkova, J.; Chait, B.T.; Landick, R.; Muir, T.; Severinov, K.; Darst, S.A. Structure of microcin J25, a peptide inhibitor of bacterial RNA polymerase, is a lassoed tail. *J. Am. Chem. Soc.* **2003**, *125*, 12475–12483.
17. Everts, S. Lassoing your target. *Chem. Eng. News* **2010**, *88*, 38–39.
18. Knappe, T. A.; Linne, U.; Robbel, L.; Marahiel, M.A. Insights into the biosynthesis and stability of the lasso peptide capistrin. *Chem. Biol.* **2009**, *16*, 1290–1298.
19. Pavlova, O.; Mukhopadhyay, J.; Sineva, E.; Ebright, R.H.; Severinov, K. Systematic structure-activity analysis of microcin J25. *J. Biol. Chem.* **2008**, *283*, 25589–25595.

20. Pan, S.J.; Link, A.J. Sequence diversity in the lasso peptide framework: discovery of functional microcin J25 variants with multiple amino acid substitutions. *J. Am. Chem. Soc.* **2011**, *133*, 5016–5023.
21. Knappe, T.A.; Manzenrieder, F.; Mas-Moruno, C.; Linne, U.; Sasse, F.; Kessler, H.; Xie, X.; Marahiel, M.A. Introducing lasso peptides as molecular scaffolds for drug design: engineering of an integrin antagonist. *Angew. Chem. Int. Ed.* **2011**, *50*, 8714–8717.
22. Leigh, D.A.; Murphy, A.; Smart, J.P.; Slawin, A. M.Z. Glycylglycine rotaxanes—The hydrogen bond directed assembly of synthetic rotaxanes. *Angew. Chem. Int. Ed.* **1997**, *36*, 728–732.
23. Clegg, W.; Gimenez-Saiz, C.; Leigh, D.A.; Murphy, A.; Slawin, A.M. Z.; Teat, S.J. “Smart” rotaxanes: Shape memory and control in tertiary amide peptide[2]rotaxanes. *J. Am. Chem. Soc.* **1999**, *121*, 4124–4129.
24. Biscarini, F.; Cavallini, M.; Leigh, D.A.; Leon, S.; Teat, S.J.; Wong, J.K.Y.; Zerbetto, F. The effect of mechanical interlocking on crystal packing: predictions and testing. *J. Am. Chem. Soc.* **2002**, *124*, 225–233.
25. Asakawa, M.; Brancato, G.; Fanti, M.; Leigh, D.A.; Shimizu, T.; Slawin, A.M.Z.; Wong, J.K.Y.; Zerbetto, F.; Zhang, S. Switching “on” or “off” the expression of chirality in peptide rotaxanes. *J. Am. Chem. Soc.* **2002**, *124*, 2939–2950.
26. Brancato, G.; Coutrot, F.; Leigh, D.A.; Murphy, A.; Wong, J.K.Y.; Zerbetto, F. From reactants to products via simple hydrogen-bonding networks: Information transmission in chemical reactions. *Proc. Natl. Acad. Sci. USA* **2002**, *99*, 4967–4971.
27. Lane, S.A.; Leigh, D.A.; Murphy, A. Peptide-based molecular shuttles. *J. Am. Chem. Soc.* **1997**, *119*, 11092–11093.
28. Wurpel, G.W.H.; Brouwer, A.M.; van Stokkum, I.H.M.; Farran, A.; Leigh, D.A. Enhanced hydrogen bonding induced by optical excitation: unexpected subnanosecond photoinduced dynamics in a peptide-based [2]rotaxane. *J. Am. Chem. Soc.* **2001**, *123*, 11327–11328.
29. Leigh, D.A.; Troisi, A.; Zerbetto, F. Reducing molecular shuttling to a single dimension. *Angew. Chem. Int. Ed.* **2000**, *39*, 350–353.
30. Hannam, J.S.; Kidd, T.J.; Leigh, D.A.; Wilson, A.J. “Magic rod” rotaxanes: The hydrogen bond-directed synthesis of molecular shuttles under thermodynamic control. *Org. Lett.* **2003**, *5*, 1907–1910.
31. Bottari, G.; Leigh, D.A.; Perez, E.M. Chiroptical switching in a bistable molecular shuttle. *J. Am. Chem. Soc.* **2003**, *125*, 13360–13361.
32. Hannam, J.S.; Lacy, S.M.; Leigh, D.A.; Saiz, C.G.; Slawin, A.M.Z.; Stitchell, S.G. Controlled submolecular translational motion in synthesis: A mechanically interlocking auxiliary. *Angew. Chem. Int. Ed.* **2004**, *43*, 3260–3264.
33. Perez, E.M.; Dryden, D.T.F.; Leigh, D.A.; Teobaldi, G.; Zerbetto, F. A generic basis for some simple light-operated mechanical molecular machines. *J. Am. Chem. Soc.* **2004**, *126*, 12210–12211.
34. Da Ros, T.; Guldi, D.M.; Morales, A.F.; Leigh, D.A.; Prato, M.; Turco, R. Hydrogen bond-assembled fullerene molecular shuttle. *Org. Lett.* **2003**, *5*, 689–691.
35. Leigh, D.A.; Thomson, A.R. Switchable dual binding mode molecular shuttle. *Org. Lett.* **2006**, *8*, 5377–5379.
36. Aucagne, V.; Leigh, D.A.; Lock, J.S.; Thomson, A.R. Rotaxanes of cyclic peptides. *J. Am. Chem. Soc.* **2006**, *128*, 1784–1785.

37. Moretto, A.; Menegazzo, I.; Crisma, M.; Shotton, E.J.; Nowell, H.; Mammi, S.; Toniolo, C. A rigid helical peptide axle for a [2]rotaxane molecular machine. *Angew. Chem. Int. Ed.* **2009**, *48*, 8986–8989.
38. Fernandes, A.; Viterisi, A.; Coutrot, F.; Potok, S.; Leigh, D.A.; Aucagne, V.; Papot, S. Rotaxane-based propeptides: Protection and enzymatic release of a bioactive pentapeptide. *Angew. Chem. Int. Ed.* **2009**, *48*, 6443–6447.
39. Fernandes, A.; Viterisi, A.; Aucagne, V.; Leigh, D.A.; Papot, S. Second generation specific-enzyme-activated rotaxane propeptides. *Chem. Commun.* **2012**, *48*, 2083–2085.
40. Cheetham, A.G.; Hutchings, M.G.; Claridge, T.D.W.; Anderson, H.L. Enzymatic synthesis and photoswitchable enzymatic cleavage of a peptide-linked rotaxane. *Angew. Chem. Int. Ed.* **2006**, *45*, 1596–1599.
41. Bao, X.; Isaacsohn, I.; Drew, A.F.; Smithrud, D.B. Determining the Intracellular Transport Mechanism of a Cleft-[2]Rotaxane. *J. Am. Chem. Soc.* **2006**, *128*, 12229–12238.
42. Coutrot, F.; Busseron, E. A new glycorotaxane molecular machine based on an anilinium and a triazolium station. *Chem. Eur. J.* **2008**, *14*, 4784–4787.
43. Gibson, H.W.; Yamaguchi, N. Formation of supramolecular polymers from homoditopic molecules containing secondary ammonium ions and crown ether moieties. *Angew. Chem. Int. Ed.* **1999**, *38*, 143–147.
44. Chiu, S.-H.; Rowan, S.J.; Cantrill, S.J.; Stoddart, J.F.; White, A.J.P.; Williams, D.J. An hermaphrodite [c2]daisy chain. *Chem. Commun.* **2002**, 2948–2949.
45. Cantrill, S.J.; Youn, G.J.; Stoddart, J.F. Supramolecular daisy chains. *J. Org. Chem.* **2001**, *66*, 6857–6872.
46. Rowan, S.J.; Cantrill, S.J.; Stoddart, J.F.; White, A.J.P.; Williams, D.J. Toward daisy chain polymers: “Wittig exchange” of stoppers in [2]rotaxane monomers. *Org. Lett.* **2000**, *2*, 759–762.
47. Loeb, S.J.; Tiburcio, J.; Vella, S. [2]Pseudorotaxane formation with *N*-benzylanilinium axles and 24-crown-8 ether wheels. *Org. Lett.* **2005**, *7*, 4923–4926.
48. Coutrot, F.; Busseron, E.; Montero, J.-L. A very efficient synthesis of a mannosyl orthoesters [2]rotaxane and mannosidic [2]rotaxanes. *Org. Lett.* **2008**, *10*, 753–756.
49. Coutrot, F.; Busseron, E. Controlling the chair conformation of a mannopyranose in a large-amplitude [2]rotaxane molecular machine. *Chem. Eur. J.* **2009**, *15*, 5186–5190.
50. Kolchinski, A.G.; Busch, D.H.; Alcock, N.W. Gaining control over molecular threading: benefits of second coordination sites and aqueous–organic interfaces in rotaxane synthesis. *J. Chem. Soc. Chem. Commun.* **1995**, 1289–1291.
51. Ashton P.R.; Campbell P.J.; Glink P.T.; Philp, D.; Spencer, N.; Stoddart, J.F.; Chrystal, E.J.T.; Menzer, S.; Williams, D.J.; Tasker, P.A. Dialkylammonium ion/crown ether complexes: the forerunners of a new family of interlocked molecules. *Angew. Chem. Int. Ed.* **1995**, *34*, 1865–1869.
52. Xue, Z.; Mayer, M.F. Actuator prototype: Capture and release of a self-entangled [1]rotaxane. *J. Am. Chem. Soc.* **2010**, *132*, 3274–3276.
53. Busseron, E.; Coutrot, F. *N*-benzyltriazolium as both molecular station and barrier in [2]rotaxane molecular machines. *J. Org. Chem.* **2013**, *78*, 4099–4106.
54. Clavel, C.; Romuald, C.; Brabet, E.; Coutrot, F. A pH-sensitive lasso-based rotaxane molecular switch. *Chem. Eur. J.* **2013**, *19*, 2982–2989.

55. Busseron, E.; Romuald, C.; Coutrot, F. Bistable or oscillating state depending on station and temperature in three-station glycorotaxane molecular machines. *Chem. Eur. J.* **2010**, *16*, 10062–10073.
56. Huisgen R. Kinetics and reaction mechanisms: selected examples from the experience of forty years. *Pure. Appl. Chem.* **1989**, *61*, 613–628.
57. Huisgen, R. 1,3-Dipolar Cycloadditions. Past and Future. *Angew. Chem. Int. Ed. Engl.* **1963**, *2*, 565–598.
58. Huisgen, R.; Szeimies, G.; Möbius, L. 1,3-Dipolare Cycloadditionen, XXXII. Kinetik der Additionen organischer Azide an CC-Mehrfachbindungen. *Chem. Ber.* **1967**, *100*, 2494–2507.
59. Huisgen, R. Kinetics and Mechanism of 1,3-Dipolar Cycloadditions. *Angew. Chem. Int. Ed. Engl.* **1963**, *2*, 633–645.
60. Kolb, H.C.; Finn, M.G.; Sharpless, K. B. Click Chemistry: Diverse Chemical Function from a Few Good Reactions. *Angew. Chem. Int. Ed.* **2001**, *40*, 2004–2021.
61. Meldal, M.; Tornøe, C.W. Cu-Catalyzed Azide–Alkyne Cycloaddition. *Chem. Rev.* **2008**, *108*, 2952–3015.
62. Castro, B.; Dormoy, J.R.; Evin, G.; Selve, C. Reactifs de couplage peptidique I (1)-l'hexafluorophosphate de benzotriazolyl N-oxytrisdiméthylamino phosphonium (B.O.P.). *Tetrahedron Lett.* **1975**, *14*, 1219–1222.
63. This compound was prepared according to the procedure described by: Angelos, S.; Yang, Y.-W.; Patel, K.; Stoddart, J.F.; Zink, J.I. pH-responsive supramolecular nanovalves based on cucurbit[6]uril pseudorotaxanes. *Angew. Chem. Int. Ed.* **2008**, *47*, 2222–2226.
64. Hünig, S.; Kiessel, M. Spezifische Protonenacceptoren als Hilfsbasen bei Alkylierungs- und Dehydrohalogenierungsreaktionen. *Chem. Ber.* **1958**, *91*, 380–392.
65. Barran, P.E.; Cole, H.L.; Goldup, S.M.; Leigh, D.A.; McGonigal, P.R.; Symes, M.D.; Wu, J.; Zengerle, M. Active-metal template synthesis of a molecular trefoil knot. *Angew. Chem. Int. Ed.* **2011**, *50*, 12280–12284.

Sample Availability: Contact the authors.

© 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (<http://creativecommons.org/licenses/by/3.0/>).